CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-52660
Recombinant Monoclonal Antibody.
![Flow Cytometry: CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric - Azide and BSA Free [NBP2-52660] Flow Cytometry: CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric - Azide and BSA Free [NBP2-52660]](https://resources.bio-techne.com/images/products/CD25-IL-2R-alpha-Antibody-Daclizumab-Chimeric-Flow-Cytometry-NBP2-52660-img0006.jpg)
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human, Cynomolgus Monkey, Rhesus Macaque
Applications
Block/Neutralize, CyTOF-ready, Flow Cytometry
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # Daclizumab
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Cultured T-cells derived from a patient with Mycosis fungoides.
Specificity
Binds to p55 chain of IL2R on human T cells, Tac antigen, which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Scientific Data Images
Flow Cytometry: CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric - Azide and BSA Free [NBP2-52660]
Flow Cytometry: CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric [NBP2-52660] - CD25/IL-2 R alpha Antibody (Daclizumab) [NBP2-52660] - Human lymphocytes were stained with an isotype control (panel A) or the rabbit-chimeric version of Daclizumab (NBP2-52660, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.Flow Cytometry: CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric - Azide and BSA Free [NBP2-52660]
Flow Cytometry: CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric [NBP2-52660] - Cynomolgus monkey lymphocytes were stained with an isotype control (red) or the rabbit-chimeric version of Daclizumab (NBP2-52660, blue) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody (ab150073) and cells analysed on a FlowJo single-cell flow cytometer.Flow Cytometry: CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric - Azide and BSA Free [NBP2-52660]
Flow Cytometry: CD25/IL-2R alpha Antibody (Daclizumab) - Chimeric [NBP2-52660] - CD25/IL-2 R alpha Antibody (Daclizumab) [NBP2-52660] - Rhesus monkey lymphocytes were stained with an isotype control (red) or the rabbit-chimeric version of Daclizumab (NBP2-52660, blue) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody (ab150073) and cells analysed on a FlowJo single-cell flow cytometer.Applications
Application
Recommended Usage
Flow Cytometry
1:10 - 1:1000
Application Notes
This antibody is Cytof ready. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Format
Azide and BSA Free
Preservative
0.02% Proclin 300
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
Background: CD25/IL-2R alpha
Long Name
Interleukin 2 Receptor alpha
Alternate Names
CD25, IL-2 R alpha, IL-2Ra, IL2R alpha, IL2RA, biosimilar antibody, biosimilars
Gene Symbol
IL2RA
Additional CD25/IL-2R alpha Products
Product Specific Notices
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...